How AI helps scientists design the next generation of medicines
AstraZeneca is using AI to accelerate the development of biologic medicines, leveraging machine learning to explore molecular combinations, prioritize candidates, and refine drug design. The company employs a build-measure-learn loop, integrating AI with human expertise to enhance efficiency and target previously untreatable diseases. By utilizing proprietary datasets, AI models are continuously refined to generate new molecular insights, supporting both drug discovery and the development of novel therapeutic approaches.
More from Technologyreview
How kids feel about AI, in their own words
When we set out to talk to kids about artificial intelligence, we thought we knew what we’d hear. We expected some to tell us they were using it to cheat a little, the way Millennials and Gen Xers opened up CliffsNotes or programmed formulas into their TI-82s, and others to share inspiring ways they were…
technologyreview.com··Mads Kristian Nylund·AI EducationAI ToolsAI Ethics
Scaling AI agents with trustworthy data
Business and technology leaders need no convincing that the time of agentic AI is here. Organizations are rapidly adopting agents, and few executives doubt the technology’s potential to transform work. But many organizations find that realizing the desired return on investment (ROI) from AI hinges on having the right foundation, with inadequate infrastructure and data…
technologyreview.com··Mads Kristian Nylund·Data InfrastructureAI GovernanceAI-agents
The Download: the next big thing in LLMs and how AI academic research is shifting
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. These startups are chasing the next big thing in LLMs Nine years after Google researchers introduced the transformer, this family of neural networks has become the engine inside every major large…
technologyreview.com··Mads Kristian Nylund·AI DevelopmentAI ToolsAI Ethics